Puneet Sood
Nephrology · San Francisco, CANPI 1194870485
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,556 of the $2,617 with a category attached, or 97.7%. Apellis Pharmaceuticals, Inc. accounts for 97.7% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $2,556, more than ten times the $12 reported in 2021.
Across 5 payments — averaging $523.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$3K
- Novartis$35
- Calliditas Therapeutics US Inc.$14
- Veloxis Pharmaceuticals, Inc.$12
Across 5 payments — averaging $8294.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$35K
- Shire North American Group Inc$6K
What the payments were for
- Consulting fees$2,55698%
- Food & beverage$351%
- Education$261%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 1 | $2,556 |
| Novartis | 1 | $35 |
| Calliditas Therapeutics US Inc. | 1 | $14 |
| Veloxis Pharmaceuticals, Inc. | 2 | $12 |
How this compares
$2,617 in reported general payments places this provider in the 65th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tacrolimus | 43 | $10,104 |
| Cinacalcet Hcl | 19 | $4,614 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $2,813 |
| Valganciclovir Hcl | 17 | $1,955 |
| Prednisone | 173 | $929 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 79 | $328 |
| Pantoprazole Sodium | 13 | $212 |
| Amlodipine Besylate | 32 | $198 |
| Metoprolol Tartrate | 18 | $96 |
| Omeprazole | 16 | $79 |
| Carvedilol | 17 | $52 |
Paid to pharmacies, not to this prescriber.
Other nephrology in San Francisco
- Meyeon ParkSan Francisco$119K
- Raymond HsuSan Francisco$77K
- Fred LuiSan Francisco$68K
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.